Aging therapies are stuck in rules built for single diseases

An analysis on Lifespan.io lays out the problem clearly. Age-related conditions such as heart disease, dementia, and cancer are still treated by regulators as separate diseases. But research shows they stem from the same underlying biological processes, described in what is known as the Hallmarks of Aging framework. New therapies target those processes, not one disease at a time.

This creates a regulatory problem. Anyone seeking approval for a therapy that addresses multiple conditions simultaneously must build a separate evidence package for each condition. Safety information is barely transferable from one condition to another. Biological aging markers, which can reflect the overall state of organs, are still rarely accepted by regulators as valid measures of success in trials. Minor improvements to an established treatment can be treated as an entirely new drug.

FDA moves cautiously in the right direction

The authors note that the FDA has so far been cautious about accepting aging biomarkers and other measures of organ rejuvenation as valid targets to test in trials. The analysis also notes that multiple aging-targeted therapies are already in or approaching trials. Pressure to adapt the regulatory framework is growing.

International fragmentation adds to the problem. Because the FDA and other regulators set different requirements, the same therapies must often be evaluated multiple times. That consumes time and funding that could go toward research.

No quick fix

The analysis does not propose a concrete timeline for when regulation will catch up. The piece is a commentary, not a study with empirical data. The conclusion is straightforward: the technology is developing faster than the rules. How that gap gets closed, and by whom, remains an open question.

Read the original article